All News

vaccination.jpg

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

EurekAlert!

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.

Read Article
Cancer.risk_.jpg

Cancer risk in rheumatoid arthritis: anything new?

Aurelie Najm, MD, PhD

Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.

Read Article
EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

Read Article
Puzzle pieces

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
@RheumNow So rheumatoid nodule treatment might target some of that pathophysiology. Rituximab, abatacept, or JAKi? And while surgery often isn’t great (plus they often grow back), definitely an option for some. Christopher Edwards #EULAR2025 @RheumNow https://t.co/sFWnQN8uC4

Links:

David Liew drdavidliew ( View Tweet)
Rheumatoid vasculitis: what to look for and how to find it #EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH

Links:

David Liew drdavidliew ( View Tweet)
How to treat rheumatoid vasculitis #EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx

Links:

David Liew drdavidliew ( View Tweet)
Should we still be worried about lymphoma developing in RA patients? Incidence has plummeted with modern therapy, although still a small risk. TNFi and other bDMARDs don’t seem to confer any real risk. So what should our approach be? Karin Hellgren #EULAR2025 @RheumNow https://t.co/9ZodpojSaz

Links:

David Liew drdavidliew ( View Tweet)
KORAIL cohort Prediction model for progression of RA-ILD at 3 years A combination of classic clinical parameters incl DA , ILD pattern, ACPA KL-6 with AUC 0.75 HR=34 for progression in High risk group Need validation in an external cohort @RheumNow #EULAR2025 OP0329 https://t.co/LIvn1JCXPq

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
🎯 Early MTX hits the mark — but only in ACPA-negative. In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years: ➖ Less RA ➖ Better function ❌ No benefit in ACPA+ Abstract#OP0324 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived phenotypes map (independent of ACPA): - to broad histopath - to MTX response Omics is good, but still need to do the simple stuff better! #EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso

Links:

David Liew drdavidliew ( View Tweet)
#neuromodulation in #rheumatoid #arthritis What is it? 👇 Autonomic & immune system interaction Who seeks this Rx? desperate pts w pain No Rx left Interested in technology #EULAR2025 @RheumNow @eular_org #D2T #RA https://t.co/XWWFiUK6Em

Links:

Janet Pope Janetbirdope ( View Tweet)
#vagal & #splenic #nerves most studied In #immune #system interaction #PNS can detect #inflammation use in #D2T #RA w active disease ? Key factors in #neurostimulation - many #EULAR2025 @RheumNow @eular_org #D2T in #RA session https://t.co/tCgpGtI5z2

Links:

Janet Pope Janetbirdope ( View Tweet)
#Vagal #nerve #stimulation Hand held device #BDMARD failure Plausible - improved pro inflammatory cytokines wears off benefit if stopped Attenuates in ~half over yrs Open label uncontrolled @RheumNow @eular_org #EULAR2025 Session D2T-RA https://t.co/98K5gwasHv

Links:

Janet Pope Janetbirdope ( View Tweet)
#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74

Links:

Janet Pope Janetbirdope ( View Tweet)
So we used to get taught about bimodal age distribution of RA onset - young people and old people. Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity Global Burden of Disease data #EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy

Links:

David Liew drdavidliew ( View Tweet)
cool stuff at #EULAR2025 RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in #RA w 1or >1 #bDMARD-IR N=242 D/C bDMARD, on #csDMARD #RA 12 yrs, 10SJC 12TJC 2.6 b/tsDMARD failure Wk12 EULAR good/mod response 61v 42% Sham▶️goes VNS ✅data= @RheumNow @eular_org abst#OP190

Janet Pope Janetbirdope ( View Tweet)

#polyrefractory #RA = failed all classes in #rheumatoid #arthritis +inflammatory #arthritis Longer disease duration Late RA Rx +power Doppler in POCUS ⬆️no refractory BMI Fibromyalgia - pain ⬇️SJC, less DAS , rapid X-ray progression #EULAR2025 @RheumNow #D2T #RA https://t.co/1sPwf3Qa3m

Links:

Janet Pope Janetbirdope ( View Tweet)
#Cancer is not ⬆️in JAKi vs #bDMARDs in #rheumatoid #arthritis When adjusted for #confounders #JAKPOT data Now you see it (unadjusted ⬆️risk) Now you don’t (adjusted =#malignancy) JAKi vs bDMARDs in RA EULAR2025 @RheumNow @eular_org #JAK it out! new perspective on JAKi https://t.co/wCQ3dHNAVa

Links:

Janet Pope Janetbirdope ( View Tweet)
#D2T #RA ~20% #Polyrefractory 3% Many reasons for d/c ing #Rx - D2T AEs Intolerance Chronic pain Etc My approach is different depending on reasons why drugs were d/c Ie ?obj inflammation vs pain or intolerance @RheumNow @eular_org #EULAR2025 #whatmakes D2T RA difficult https://t.co/AL6TMVJIk9

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×